It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC
Despite innovative advances in molecular targeted therapy, treatment strategies using immune checkpoint inhibitors (ICIs) for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) have not progressed significantly. Accumulating evidence suggests that ICI chemotherapy is i...
Salvato in:
| Autori principali: | , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Open Exploration Publishing Inc.
2024-07-01
|
| Serie: | Exploration of Targeted Anti-tumor Therapy |
| Soggetti: | |
| Accesso online: | https://www.explorationpub.com/Journals/etat/Article/1002251 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|